HER2+ Breast Cancer

Debu Tripathy, MD, discusses treatment de-escalation in HER2-positive breast cancer.

William J. Gradishar, MD, discusses the expanding role of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Claudine Isaacs, MD, discusses the rapidly evolving HER2-positive breast cancer armamentarium.

Sara M. Tolaney, MD, MPH, discusses escalating versus de-escalating therapies in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the potential role of fam-trastuzumab deruxtecan-nxki in patients with HER2-positive breast cancer and brain metastases.

In an interview with OncLive Ruth O’Regan, MD, discusses the challenges faced with personalizing treatment in early-stage HER2-positive breast cancer

New approaches for treating patients with HER2-positive metastatic breast cancer are showing signs of efficacy against brain metastases, generating excitement about the potential to make critical advances and sparking questions about optimal sequencing.

Elisavet Paplomata, MD, discusses the role of tucatinib ​in combination with trastuzumab and capecitabine in HER2-positive metastatic breast cancer.

Ruth O’Regan, MD, discusses the role of therapy escalation in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the challenges in treating patients with heterogenous HER2 expression and what treatments could potentially improve outcomes for this subgroup.

Elisavet Paplomata, MD, discusses management strategies for fam-trastuzumab deruxtecan-nxki–induced interstitial lung disease in HER2-positive breast cancer.

Ruth O’Regan, MD, discusses the risk of cardiomyopathy associated with trastuzumab in HER2-positive breast cancer.

William J. Gradishar, MD, discusses the ​current treatment landscape in metastatic HER2-positive breast cancer.

Nancy U. Lin, MD, discusses the challenges faced in the treatment of patients with HER2-positive breast cancer and brain metastases.

Women with early-stage HER2-positive breast cancer who achieved a pathologic complete response to neoadjuvant HER2-directed therapy experienced prolonged event-free survival and overall survival versus those who did not.

Elisavet Paplomata, MD, discusses the clinical impact of tucatinib in HER2-positive breast cancer.

Neratinib was shown to have a numerical overall survival benefit in addition to improvements in invasive disease-free survival and central nervous system recurrence in patients with HER2-positive, hormone receptor–positive, early stage breast cancer.

Erika P. Hamilton, MD, discusses the exploration of CDK4/6 Inhibitors in HER2-positive breast cancer.

Sara M. Tolaney, MD, MPH, discusses the evolution of treatment in HER2-positive breast cancer.

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

In our exclusive interview, Dr. Tripathy discusses the state of treatment in metastatic HER2-positive breast cancer, current sequencing strategies, and targeted agents under evaluation in this setting.

The addition of tucatinib to trastuzumab and capecitabine in patients with HER2-positive metastatic breast cancer with and without brain metastases resulted in statistically significant and clinically meaningful improvements in progression-free and overall survival.

A panel of breast cancer experts discuss a variety of new and emerging agents to treat patients with advanced or metastatic HER2-positive breast cancer with disease progression following treatment with at least 1 anti-HER2 therapy.

Heather ​S. Han, MD, discusses the benefit of adding pertuzumab to trastuzumab and chemotherapy in the phase 3 APHINITY trial in patients with HER2-positive early-stage breast cancer.

In our exclusive interview, Sara M. Tolaney, MD, MPH, shares insight on how risk status is being used to tailor HER2-directed therapies to patients with early-stage HER2-positive breast cancer, key trials focused on delineating optimal deescalated and escalated treatment strategies, and ongoing research in the HER2-low setting.